Literature DB >> 15167101

Validation of a new method for quantifying in vivo murine tumor necrosis by sonography.

Valérie Rouffiac1, Céline Bouquet, Nathalie Lassau, Paule Opolon, Serge Koscielny, Pierre Peronneau, Michel Perricaudet, Alain Roche.   

Abstract

RATIONALE AND
OBJECTIVES: At present, the gold standard to evaluate tumor necrosis is histology. We described here a new method to quantify the degree of tumor necrosis by ultrasonography. This technique combines ultrasound exploration of tissue and post-treatment of the numerical sequences using a dedicated software to evaluate backscattered power within the tumor.
MATERIALS AND METHODS: In order to establish that the backscattered power could be considered as a relevant marker of tumor necrosis, we performed (1) intra- and interoperator reproducibility in estimation of tumor dimensions obtained on sonographic scans; and (2) intra- and interoperator reproducibility in quantification of backscattered power in postprocessing using the HDILab software. The third part of the study consisted of correlating the degree of tumor necrosis estimated by histology and the ultrasound backscattered power, both obtained on xenografted melanomas at different days after tumor transplantation.
RESULTS: Results concerning tumor size estimations and quantification of echogenicity were reproducible (coefficient of variation < 4.33%). The degree of necrosis measured in histology and echogenicity were significantly negatively correlated (P < 0.003).
CONCLUSION: In conclusion, backscattered power could be considered as a relevant parameter to quantify tumor necrosis in vivo.

Entities:  

Mesh:

Year:  2004        PMID: 15167101     DOI: 10.1097/01.rli.0000124457.99229.bb

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  7 in total

Review 1.  Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.

Authors:  Christian Kollmannsberger; Georg Bjarnason; Patrick Burnett; Patricia Creel; Mellar Davis; Nancy Dawson; Darren Feldman; Suzanne George; Jerome Hershman; Thomas Lechner; Amy Potter; Eric Raymond; Nathaniel Treister; Laura Wood; Shenhong Wu; Ronald Bukowski
Journal:  Oncologist       Date:  2011-04-13

Review 2.  Targeted therapies in renal cell cancer: recent developments in imaging.

Authors:  Astrid A M van der Veldt; Martijn R Meijerink; Alfons J M van den Eertwegh; Epie Boven
Journal:  Target Oncol       Date:  2010-07-14       Impact factor: 4.493

3.  Early treatment response to sorafenib for rabbit VX2 orthotic liver tumors: evaluation by quantitative contrast-enhanced ultrasound.

Authors:  Wen-Tao Kong; Hai-Xia Yuan; Hao Cai; Wen-Ping Wang; Yang Tang; Xiao-Long Zhang
Journal:  Tumour Biol       Date:  2014-12-02

4.  Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential.

Authors:  Catherine Delbaldo; Sandrine Faivre; Chantal Dreyer; Eric Raymond
Journal:  Ther Adv Med Oncol       Date:  2012-01       Impact factor: 8.168

5.  Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients?

Authors:  Mohmad Hussain Mir; Khalid Hamid Changal; Shiekh Aejaz Aziz; Gull Mohammad Bhat; Abdul Rashid Lone
Journal:  Int Urol Nephrol       Date:  2016-07-23       Impact factor: 2.370

6.  Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects.

Authors:  C Kollmannsberger; D Soulieres; R Wong; A Scalera; R Gaspo; G Bjarnason
Journal:  Can Urol Assoc J       Date:  2007-06       Impact factor: 1.862

7.  Quantitative evaluation of cell death response in vitro and in vivo using conventional-frequency ultrasound.

Authors:  Ali Sadeghi-Naini; Stephanie Zhou; Mehrdad J Gangeh; Zahra Jahedmotlagh; Omar Falou; Shawn Ranieri; Muhammad Azrif; Anoja Giles; Gregory J Czarnota
Journal:  Oncoscience       Date:  2015-09-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.